VKTX240705P49000
- 0.04
- 0.000.00%
Viking Therapeutics Newsroom
Oppenheimer's Top SMID Ideas Within High-growth Themes
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Better GLP-1 Biotech Stock: Altimmune Vs. Viking Therapeutics
PwC: Patent cliff boosts acquisition interest of pharmaceutical giants, and small and medium-sized biotechnology companies become "hot cakes".
PwC said that many large pharmaceutical companies are facing an imminent patent cliff that will impact the sales of key drugs, which may prompt them to engage in more mergers and acquisitions of small and medium-sized biotechnology companies to offset revenue losses.
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX).And retail traders should know.We noticed this today when the trades showed up on publicly avail
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
BTIG analyst Justin Zelin maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 37.8% and a t
Optimistic Outlook for Viking Therapeutics' Obesity Treatments Amid Upcoming Catalysts and Regulatory Progress
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $110
Jefferies analyst Roger Song maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $110.According to TipRanks data, the analyst has a success rate of 29.1% and
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 33.85% on an annualized basis producing an average annual return of 46.66%. Currently, Viking Therapeutics has a
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Stifel analyst Annabel Samimy maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 43.2% and
Stifel Nicolaus Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Express News | Viking Therapeutics Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Target Price $105
What Makes Viking Therapeutics, Inc. (VKTX) One of the Best Healthcare Stocks to Buy Under $50?